NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference

NXTC 11.26.2024

Full Press ReleaseSEC FilingsOur NXTC Tweets

About Gravity Analytica

Recent News

  • 01.10.2025 - NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers
  • 12.10.2024 - NextCure Announces Acceptance of IND Application for LNCB74
  • 12.05.2024 - 36th Annual Piper Sandler Healthcare Conference

Recent Filings

  • 01.10.2025 - 8-K Current report
  • 01.10.2025 - EX-99.1 EX-99.1
PDF Version

BELTSVILLE, Md.,Nov. 26, 2024(GLOBE NEWSWIRE) --NextCure, Inc.(Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that it will participate in a fireside chat at the 36th AnnualPiper Sandler Healthcare ConferenceinNew York CityonThursday, December 5, at12:00 pm ET.

A live audio webcast will be available through the Investors section of the company’s website atwww.nextcure.com. A replay of the webcast will be available after the event and archived on the website for 30 days.

AboutNextCure, Inc.NextCureis a clinical-stage biopharmaceutical company that is focused on advancing innovative medicines that treat cancer patients that do not respond to, or have disease progression on, current therapies, through the use of differentiated mechanisms of actions including antibody-drug conjugates, antibodies and proteins. We focus on advancing therapies that leverage our core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response.http://www.nextcure.com

Cautionary Statement Regarding Forward-Looking StatementsStatements made in this press release that are not historical facts are forward-looking statements. Words such as “expects,” “believes,” “intends,” “hope,” “forward” and similar expressions are intended to identify forward-looking statements. Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those projected in any forward-looking statement. Such risks and uncertainties include, among others: our limited operating history and no products approved for commercial sale; our history of significant losses; our need to obtain additional financing; risks related to clinical development, including that early clinical data may not be confirmed by later clinical results; risks that pre-clinical research may not be confirmed in clinical trials; risks related to marketing approval and commercialization; and NextCure’s dependence on key personnel. More detailed information on these and additional factors that could affect NextCure’s actual results are described in NextCure’s filings with theSecurities and Exchange Commission(the “SEC”), including NextCure’s most recent Form 10-K and subsequent Form 10-Q. Youshould not place undue reliance on any forward-looking statements.NextCureassumes no obligation to update any forward-looking statements, even if expectations change.

Investor InquiriesTimothy Mayer, Ph.D.NextCure, Inc.Chief Operating Officer(240) 762-6486IR@nextcure.com

Primary Logo

Source: NextCure

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com